Scalper1 News
Jazz Pharmaceuticals (JAZZ) got a downgrade — but also several price target hikes — in the wake of its Q4 earnings report late Tuesday, sending the stock plunging, then partly recovering, in the stock market today. Jazz missed Q4 estimates but guided 2014 financials above expectations. Cantor Fitzgerald analyst Irina Rivkind downgraded Jazz stock to hold from buy, focusing on the firm’s ongoing difficulties with the FDA concerning the risk Scalper1 News
Scalper1 News